Module 8: Reproductive/Developmental and Juvenile Toxicology
Recorded On: 08/05/2021
This module aims to provide an overview of Reproductive, Developmentalม and Juvenile Toxicology with a focus on the nonclinical testing of drugs, medical devices, and vaccines (intentional exposures) and chemicals, food additives, etc. (unintentional exposures), for effects on male and female fertility and early embryonic development, embryofetal development (EFD), pre- and postnatal (PPND) development and direct exposure postnatally.
The regulatory guidance for testing of reproductive and developmental drugs and chemical toxicants, including the newly approved ICH S5(R3) (18 Feb 2020) and OECD 421/422/414/443, will be discussed. Included are overviews of study designs, reasons for species selection, and appropriate age of animals for testing. The presentation will cover the various stages of male and female fertility/reproduction, fetal development and growth, and development of future generations; data interpretations on the toxicity endpoints (paternal/maternal/ developmental/juvenile) and outcomes, including the establishment of a no-observed-adverse-effect-level (NOAEL) and hazard assessments. The reproductive and developmental testing of biologics, biopharmaceuticals, and vaccines, including species selection, enhanced/combined study designs, appropriate organ and other toxicity assessments, and outcomes, are also discussed.
The last part of this module will focus on the principles of Juvenile Toxicology and address whether a juvenile animal study should be conducted, the timing of juvenile studies when needed, and how it should be conducted. An overview of juvenile toxicology guidelines, including the ICH S11 guidance for nonclinical juvenile animal testing to support pediatric medicine development will be presented. This will include a weight-of-evidence approach to decide when a juvenile animal study is warranted. Topics addressed will include selection of juvenile toxicology species, age of the animals, dose range finding, and ADME considerations in juvenile animals. Lastly, interpretation considerations unique to juvenile animal studies and application of results to human risk assessment will be discussed with a focus on pharmaceuticals.
Alan M. Hoberman, PhD, DABT, ATS
President
Argus International, Inc.
Dr. Alan Hoberman has been employed by Charles River Laboratories, Horsham, Pennsylvania (formerly Argus Research Laboratories, Inc.) since 1981, serving as Study Director, Director of Reproductive Toxicology, Executive Director, Global Developmental, Reproductive and Juvenile Toxicology and Scientific Advisor. He is also the President of Argus International Inc. a consulting company. Prior to joining Argus Research, Dr. Hoberman was the Head of Reproductive Toxicology at Hazleton Laboratories in Vienna, Virginia. He received his BS in Biology from Drexel University and was a graduate student in Anatomy at the University of Virginia before moving to Arkansas and completing a MS in Interdisciplinary Toxicology from the University of Arkansas and a PhD in Toxicology from Pacific Western University.
He is a Diplomat of the American Board of Toxicology since 1988 and a Fellow of the Academy of Toxicological Sciences since 2006, with over 95 publications and book chapters. He is the co-editor of “Pediatric Non-Clinical Drug Testing, Principles, Requirements, and Practices” published in January 2012.
Dr. Hoberman has been a member of Birth Defects Research and Prevention since 1978 and is a Past President. He is also a member of the European Teratology Society since 1982 and past councilor. He has been a member of the American College of Toxicology since 1979 and is a Past President. He is a Past President of the Reproductive and Developmental Toxicity Specialty Section of the Society of Toxicology, the Middle Atlantic Reproductive and Teratology Association, and the Arkansas Biotechnology Organization. He currently represents the 3Rs Collaborative on the Scientific Liaison Collation.